Navigation Links
WuXi PharmaTech Announces Purchase of Ordinary Shares from General Atlantic
Date:2/15/2012

SHANGHAI, Feb. 15, 2012 /PRNewswire-Asia/ -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology, and medical-device research and development outsourcing company, with operations in China and the United States, announced that today it had in a negotiated transaction agreed to purchase from investment funds affiliated with global growth investor General Atlantic LLC ("General Atlantic") all of the WuXi ordinary shares General Atlantic received on February 12, 2012, following the conversion in full of the $35 million principal amount of convertible notes plus accrued interest of approximately $864,000 held by General Atlantic. The per-ADS equivalent purchase price of $13 was established based on a discount of slightly over 5% of the ADS closing price on February 13, 2012. The transaction was reviewed and approved by the disinterested members of the audit committee of WuXi's board of directors. WuXi expects the transaction to close on or about February 24, 2012. WuXi will use existing cash balances to pay for the transaction.

In February 2007, third-party investors, including General Atlantic, purchased $40 million principal amount of convertible notes from WuXi, with the notes maturing on February 9, 2012. In 2008, $5 million principal amount of notes were converted into ordinary shares. On February 7, 2012, General Atlantic elected to convert the remaining $35 million principal amount of notes plus accrued interest of approximately $864,000 into 22,771,000 ordinary shares at a conversion price of $1.575 per ordinary share, equivalent to 2,846,375 ADSs and a per-ADS conversion price of $12.60.

The potential impact of the conversion of the notes to ordinary shares has been reflected in the earnings per share calculations in WuXi's previous financial reporting, in accordance with generally accepted accounting principles. With WuXi's purchase of these shares t
'/>"/>

SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. WuXi PharmaTech Schedules Fourth-Quarter 2011 Earnings Release
2. WuXi PharmaTech Provides Update of 2011 Financial Guidance, to Present at J.P. Morgan Healthcare Conference
3. WuXi PharmaTech Presents the 2011 Life Science and Chemistry Awards
4. WuXi PharmaTech Schedules Third-Quarter 2011 Earnings Release
5. WuXi PharmaTech Acquires China-Based Clinical Research Services Companies
6. WuXi PharmaTech Announces Second Quarter 2011 Results
7. WuXi PharmaTech Announces Shareholder Resolutions Adopted at 2011 Annual General Meeting
8. WuXi PharmaTech Schedules Second-Quarter 2011 Earnings Release
9. WuXi PharmaTech Announces First-Quarter 2011 Results
10. WuXi PharmaTech Files 2010 Annual Report on Form 20-F
11. WuXi PharmaTech Schedules First-Quarter 2011 Earnings Release
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... and CHESTERBROOK, Pa. , Sept. 18, ... VVUS ) and Auxilium Pharmaceuticals, Inc. (Nasdaq: ... Drug Administration (FDA) has approved a supplemental new drug application ... only FDA-approved erectile dysfunction (ED) medication indicated to be taken ... STENDRA is a prescription medication in a class of ...
(Date:9/17/2014)... , Sept. 17, 2014 BRIC Gynecological ... GlobalData,s new report, "BRIC Gynecological ... data on the BRIC Gynecological Devices market. The ... volume (in units) and average prices (in US ... (Transcervical Sterilization Devices (Micro-inserts) and Mechanical Sterilization Devices ...
(Date:9/17/2014)... MONICA, Calif. , Sept. 17, 2014  Dr. ... is at the White House today for National Recovery ... 46 that consumer advocates released today. Consumer advocates were ... woman who spoke out after losing her fiancée ... discovering that the doctor had a history of crack ...
Breaking Medicine Technology:VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 2VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 3VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 4VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 5VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 6VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 7VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 8VIVUS And Auxilium Announce FDA Approval Of STENDRA sNDA; STENDRA Now First And Only Oral Erectile Dysfunction Treatment Approved To Be Taken Approximately 15 Minutes Before Sexual Activity 9BRIC Gynecological Devices Market Outlook to 2020 2BRIC Gynecological Devices Market Outlook to 2020 3Doctor Recovering From 100-Pill-A-Day Addiction Stars In New Ad Supporting Prop 46; Appears At White House for National Recovery Month, Says Consumer Watchdog Campaign 2Doctor Recovering From 100-Pill-A-Day Addiction Stars In New Ad Supporting Prop 46; Appears At White House for National Recovery Month, Says Consumer Watchdog Campaign 3
... 18, 2011 Adeona Pharmaceuticals, Inc. (Amex: ... central nervous system diseases, announced today that it will ... 8, 2011 from 3:00-5:00 P.M. (EST) at the Kensington ... Arbor, Adeona,s management team welcomes shareholders, potential investors and ...
... Companion Animal Health has launched its second product in ... + milbemycin oxime), a broad-spectrum parasiticide that kills fleas ... flea infestations, the prevention of heartworm disease and the ... infections in dogs and puppies 8 weeks and older, ...
Cached Medicine Technology:Adeona to Host Investor Day on Zinc Deficiency in Alzheimer's Disease 2Adeona to Host Investor Day on Zinc Deficiency in Alzheimer's Disease 3Elanco Launches Broad-Spectrum Canine Parasiticide 2Elanco Launches Broad-Spectrum Canine Parasiticide 3Elanco Launches Broad-Spectrum Canine Parasiticide 4
(Date:9/18/2014)... 2014 With the development of ... of adjusting human body physiology, preventing diseases, promoting ... with a variety of specific populations. In 2013, ... reached RMB187.4 billion, up 12.0% year on year, ... View Full Report at http://www.marketresearchreports.biz/analysis/223449 , ...
(Date:9/18/2014)... MA (PRWEB) September 18, 2014 ... its team and surgeon partners in Less Exposure ... joining SpineFrontier, Tamara authored an extensive education curriculum ... a Masters in Science in Organizational Leadership, and ... industries for eleven years. Bringing her to the ...
(Date:9/18/2014)... Dr. Suzaunna Clark, Psychologist, Life Coach ... beauty has to be seen to be believed and ... order to be used. Together, both lead to hearts ... how to do both. , Dr. Clark ... Healing Hearts system, which provides professional guidance on dealing ...
(Date:9/18/2014)... Specialty Teleradiology LLC, a provider of teleradiology services ... achieved Meaningful Use and increased operational efficiency since ... developed by RamSoft. , Before implementing PowerServer ... PACS and a RIS that was built in-house. ... oncology to other subspecialties, they needed a robust, ...
(Date:9/18/2014)... 2014 N-Zyme Scientifics LLC achieved a ... first product a mere 8 months after company startup. ... performance glycan release enzyme used in the “Biologics” industry ... basis for tissue pathology on Mass Spec devices. PRIME™ ... the North American market (PNGase F PRIMETM). N-Zyme ...
Breaking Medicine News(10 mins):Health News:China Health Food Industry Size 2014 Market Analysis, Growth, Trends and Forecast Report 2017: MarketResearchReports.biz 2Health News:China Health Food Industry Size 2014 Market Analysis, Growth, Trends and Forecast Report 2017: MarketResearchReports.biz 3Health News:China Health Food Industry Size 2014 Market Analysis, Growth, Trends and Forecast Report 2017: MarketResearchReports.biz 4Health News:SpineFrontier Inc. Makes Bold Move to Expand Its Internal Training Team to Collaborate With The LESSociety’s Less Exposure Surgery® University To Educate Surgeons. 2Health News:Suzaunna-Where Life! Happens Announces the Launch of Healing Hearts 2Health News:Suzaunna-Where Life! Happens Announces the Launch of Healing Hearts 3Health News:Specialty Teleradiology Attains Meaningful Use with PowerServer MU 2Health News:Specialty Teleradiology Attains Meaningful Use with PowerServer MU 3Health News:N-Zyme Scientifics Announces Successful Product Launch 2
... latest research unhealthy ways of expressing anger are associated ... //expressing anger." According to past research, stress can also ... not practice healthy anger or stress management may be ... adolescents, ages 14 to 17, for three years. In ...
... New research shows one virus could help fight another. ... // hepatitis G , may hold a key ... ,Researchers analyzed results from the Multicenter Acquired ... large group of HIV-infected men in the United States ...
... put a woman at increased risk of developing asthma, report ... obstructive pulmonary disease (COPD) risk. ,The incidence of both ... 5 percent to 8 percent of Americans have asthma, and ... since 1982. Since the prevalence of asthma tends to change ...
... lose significant bone mass in the first year after the ... their bodies from rejecting the new organ. The bone loss ... of fractures among this group ranges from 22 percent to ... treatment, but which drugs work best in this situation is ...
... is showing promising results.For the past decade, researchers // ... immunotoxin is bioengineered and consists of only the most ... commonly used to fight leukemia. One of those immunotoxins, ... study. ,Researchers say in a phase I study, ...
... estimates that 40 million people are infected with the ... In some African countries, 40 percent of pregnant women ... caught HIV. ,In impoverished areas where the ... one-time treatment for HIV-infected pregnant women to keep them ...
Cached Medicine News:Health News:Drug to stop HIV spread to babies may Indirectly harm The Mother 2
... Alliance Catheter Delivery System (CDS) ... stabilization of the Aescula LV ... has a patented coronary sinus ... and easy access to the ...
... PCS2 system is Haemonetics ... collection of plasma and ... the collection of "jumbo" ... platelet-poor plasma with optional ...
Optipress II Automated Blood Component Extractor for the standardized separation of whole blood into high purity individual components...
... Pipette* provides quick, convenient, repetitive dispensing ... Combitips have a polyethylene plunger and ... for use with most reagents. ... Five separate volumes can be selected ...
Medicine Products: